Mark Stein
Overview
Explore the profile of Mark Stein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tandon P, Gabert T, Kuhn M, Tran N, Ola C, Sullivan E, et al.
J Pediatr Psychol
. 2024 Sep;
49(9):664-675.
PMID: 39279226
Objective: Parent behavior management training (BMT) is an evidence-based yet underutilized tool to treat children with ADHD and address related health disparities. This pilot study investigated the acceptability and feasibility...
2.
Barata P, Tangen C, Plets M, Thompson Jr I, Narayan V, George D, et al.
J Clin Oncol
. 2024 Sep;
42(33):3911-3916.
PMID: 39255440
JCO Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057),...
3.
Taylor B, Ponsonby A, Stein M, Lucas R, Morahan J, Dear K, et al.
Brain
. 2024 Jul;
147(10):e66-e67.
PMID: 39028680
No abstract available.
4.
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604810
Background: As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy;...
5.
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, et al.
J Immunother Cancer
. 2023 Mar;
11(3.
PMID: 36948504
Background: To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with...
6.
Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36822667
Background: Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and...
7.
Buitelaar J, Bolte S, Brandeis D, Caye A, Christmann N, Cortese S, et al.
Front Behav Neurosci
. 2022 Jul;
16:900981.
PMID: 35874653
Attention-Deficit Hyperactivity Disorder (ADHD) is a complex and heterogeneous neurodevelopmental condition for which curative treatments are lacking. Whilst pharmacological treatments are generally effective and safe, there is considerable inter-individual variability...
8.
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, et al.
J Clin Oncol
. 2022 Apr;
40(25):2913-2923.
PMID: 35442713
Purpose: To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma...
9.
Wasserman R, Gupta S, Stein M, Rabbat C, Engl W, Leibl H, et al.
Immunotherapy
. 2021 Dec;
14(4):215-224.
PMID: 34931880
This analysis evaluated the efficacy and overall tolerability of immunoglobulin (Ig) treatment modalities (intravenous Ig [iv.Ig], subcutaneous Ig [sc.Ig] and facilitated sc.Ig [fsc.Ig]). A total of 30 participants with primary...
10.
Norman S, Atabaki S, Atmore K, Biddle C, DiFazio M, Felten D, et al.
Clin Child Psychol Psychiatry
. 2021 Dec;
27(1):244-258.
PMID: 34923834
Delivery of mental health treatment in the home can close gaps in care. Telehealth also provides access to healthcare that has been disrupted due to the COVID-19 pandemic. In 2016,...